170 related articles for article (PubMed ID: 38376408)
1. The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma.
Bai J; Li X; Wen Y; Lu Q; Chen R; Liu R; Shangguan T; Ye Y; Lin J; Cai W; Kang D; Chen J
Aging (Albany NY); 2024 Feb; 16(4):3631-3646. PubMed ID: 38376408
[TBL] [Abstract][Full Text] [Related]
2. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
[TBL] [Abstract][Full Text] [Related]
3. Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration.
Muller M; Guillaud-Bataille M; Salleron J; Genestie C; Deveaux S; Slama A; de Paillerets BB; Richard S; Benusiglio PR; Ferlicot S
Mod Pathol; 2018 Jun; 31(6):974-983. PubMed ID: 29410489
[TBL] [Abstract][Full Text] [Related]
4. The use of Clinicopathological, immunohistochemistry and molecular detection in the diagnosis of fumarate hydratase-deficient uterine leiomyomas.
Zhang X; Wang C; Shen D
Pathol Res Pract; 2024 Jan; 253():154916. PubMed ID: 38029712
[TBL] [Abstract][Full Text] [Related]
5. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
[TBL] [Abstract][Full Text] [Related]
6. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
[TBL] [Abstract][Full Text] [Related]
7. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR
Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276
[TBL] [Abstract][Full Text] [Related]
8. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry.
Chen YB; Brannon AR; Toubaji A; Dudas ME; Won HH; Al-Ahmadie HA; Fine SW; Gopalan A; Frizzell N; Voss MH; Russo P; Berger MF; Tickoo SK; Reuter VE
Am J Surg Pathol; 2014 May; 38(5):627-37. PubMed ID: 24441663
[TBL] [Abstract][Full Text] [Related]
9. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.
Alam NA; Rowan AJ; Wortham NC; Pollard PJ; Mitchell M; Tyrer JP; Barclay E; Calonje E; Manek S; Adams SJ; Bowers PW; Burrows NP; Charles-Holmes R; Cook LJ; Daly BM; Ford GP; Fuller LC; Hadfield-Jones SE; Hardwick N; Highet AS; Keefe M; MacDonald-Hull SP; Potts ED; Crone M; Wilkinson S; Camacho-Martinez F; Jablonska S; Ratnavel R; MacDonald A; Mann RJ; Grice K; Guillet G; Lewis-Jones MS; McGrath H; Seukeran DC; Morrison PJ; Fleming S; Rahman S; Kelsell D; Leigh I; Olpin S; Tomlinson IP
Hum Mol Genet; 2003 Jun; 12(11):1241-52. PubMed ID: 12761039
[TBL] [Abstract][Full Text] [Related]
10. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.
Bardella C; El-Bahrawy M; Frizzell N; Adam J; Ternette N; Hatipoglu E; Howarth K; O'Flaherty L; Roberts I; Turner G; Taylor J; Giaslakiotis K; Macaulay VM; Harris AL; Chandra A; Lehtonen HJ; Launonen V; Aaltonen LA; Pugh CW; Mihai R; Trudgian D; Kessler B; Baynes JW; Ratcliffe PJ; Tomlinson IP; Pollard PJ
J Pathol; 2011 Sep; 225(1):4-11. PubMed ID: 21630274
[TBL] [Abstract][Full Text] [Related]
11. Fumarate Hydratase-Deficient Leiomyoma of the Uterine Corpus: Comparative Morphologic Analysis of Protein-Deficient Tumors With and Without Pathogenic Germline Fumarate Hydratase Gene Mutations.
Shi W; Liu Y; Aisagbonhi O; Roma AA; Hasteh F; Zare SY; Fadare O
Int J Surg Pathol; 2024 Apr; 32(2):340-355. PubMed ID: 37312573
[TBL] [Abstract][Full Text] [Related]
12. Cryptic splice mutation in the fumarate hydratase gene in patients with clinical manifestations of Hereditary Leiomyomatosis and Renal Cell Cancer.
Crooks DR; Cawthon GM; Fitzsimmons CM; Perez M; Ricketts CJ; Vocke CD; Yang Y; Middelton L; Nielsen D; Schmidt LS; Tandon M; Merino MJ; Ball MW; Meier JL; Batista PJ; Linehan WM
Hum Mol Genet; 2023 Nov; 32(22):3135-3145. PubMed ID: 37561409
[TBL] [Abstract][Full Text] [Related]
13. Multidetector CT Characteristics of Fumarate Hydratase-Deficient Renal Cell Carcinoma and Papillary Type II Renal Cell Carcinoma.
Yang L; Li XM; Hu YJ; Zhang MN; Yao J; Song B
Korean J Radiol; 2021 Dec; 22(12):1996-2005. PubMed ID: 34668351
[TBL] [Abstract][Full Text] [Related]
14. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Smith SC; Trpkov K; Chen YB; Mehra R; Sirohi D; Ohe C; Cani AK; Hovelson DH; Omata K; McHugh JB; Jochum W; Colecchia M; Amin M; Divatia MK; Hes O; Menon S; Werneck da Cunha I; Tripodi S; Brimo F; Gill AJ; Osunkoya AO; Magi-Galluzzi C; Sibony M; Williamson SR; Nesi G; Picken MM; Maclean F; Agaimy A; Cheng L; Epstein JI; Reuter VE; Tickoo SK; Tomlins SA; Amin MB
Am J Surg Pathol; 2016 Nov; 40(11):1457-1472. PubMed ID: 27635946
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of somatic and germline mutations of Fumarate hydratase in uterine leiomyomas from young patients.
Liu C; Dillon J; Beavis AL; Liu Y; Lombardo K; Fader AN; Hung CF; Wu TC; Vang R; Garcia JE; Xing D
Histopathology; 2020 Feb; 76(3):354-365. PubMed ID: 31564060
[TBL] [Abstract][Full Text] [Related]
16. A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression.
Anderson WJ; Tsai HK; Sholl LM; Hirsch MS
Int J Surg Pathol; 2022 Sep; 30(6):606-615. PubMed ID: 35048731
[No Abstract] [Full Text] [Related]
17. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
[TBL] [Abstract][Full Text] [Related]
18. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
[TBL] [Abstract][Full Text] [Related]
19. Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer.
Alam NA; Olpin S; Rowan A; Kelsell D; Leigh IM; Tomlinson IP; Weaver T
J Mol Diagn; 2005 Oct; 7(4):437-43. PubMed ID: 16237213
[TBL] [Abstract][Full Text] [Related]
20. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]